C-H3U4Mirscience Therapeutics
microRNA, oligonucleotides, MIR-Discovery
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-H3U4
C-H3U4C-H3U4microRNA, oligonucleotides, MIR-Discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
FDA Approvals for Novo Nordisk WEGOVY, Ascendis Pharma TransCon CNP, Otsuka VOYXACT, Sarepta ENDEAVOR, AstraZeneca IMFINZI | DelveInsight Business Research LLP posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your setting … ases, nephrology, gene therapy, and oncology: 1️⃣ Novo Nordisk submitted an FDA application for a higher 7.2 mg dose of WEGOVY, showing 20.7% average weight loss versus 17.5% for the 2.4 mg dose, under expedited review via the Commissioner's National Priority Voucher program. 2️⃣ Ascendis Pharma received an FDA review extension for TransCon CNP in pediatric achondroplasia, with the new PDUFA date. 3️⃣ Otsuka Pharmaceutical Co., Ltd. secured FDA Accelerated Approval for VOYXAC … for patients across the globe. Equally noteworthy is an innovative gene therapy application that seeks FDA approval, which could revolutionize the management of previously intractable genetic diseases. This promises to be a landmark achievement in precision medicine, enabling tailored interventions based on individual genetic profiles. Both the scientific community and stakeholders remain optimistic as we anticipate these outcomes. Approval of these pioneering therapies could … al stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Series A represents an important inflection point for Rezubio,” said Yusheng Xiong, PhD, co-founder and CEO of Rezubio. “Membrane anchoring has the potential to reshape how targeted medicines are designed. Our MADD platform enables highly localized pharmacology for cell-surface targets, including GPCRs, while minimizing systemic exposure. Our gut-targeted GPCR ago … ’s Sotyktu, the first approved TYK2 inhibitor for psoriasis. 🔵 Takeda plans to submit regulatory filings in the U.S. and other markets during fiscal year 2026, with additional studies ongoing across arthritis, ulcerative colitis, and other indications. The Phase 3 results were generated from two large trials enrolling 693 and 1,108 participants,
Sarcopenia Market to Grow Rapidly by 2034, Key Players: TNF Pharma, Lipocine | Abhivandan Nagia posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression | ChAbS (Chinese Antibody Society) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can upda … in two pivotal Phase 3 trials, strengthening confidence as @Praxis prepares to submit an NDA in early 2026 following a successful pre-NDA meeting with the FDA. 🧬 3️⃣ Novel Mechanism, Clear Differentiation Ulixacaltamide is a highly selective T-type calcium channel inhibitor, designed to suppress abnormal neuronal burst firing in the cerebello–thalamo–cortical (CTC) circuit—a mechanism tightly linked to tremor generation. This is not another repurposed beta-blocker. 📊 4️⃣ L … 2025 ⸻ 🏛️ Policy, Regulation & Strategy ⚖️ Eli Lilly and Company files FDA application for its obesity pill orforglipron using a rare “national priority” voucher to ускорate review. 🌍 The European Commission unveils early elements of a Biotech Act: €10B BioTechEU funding (2026–27), faster multinational trials, and potential longer IP protection. 🏭 AstraZeneca CEO Pascal Soriot warns Europe could stop producing innovative medicines within 15 years without stronger indus … CEPI (Coalition for Epidemic Preparedness Innovations) commits up to $54.3M to fund Moderna’s Phase 3 pandemic flu (H5) mRNA vaccine. ⸻ 🌍 Global & Public Health 🌍 Novo Nordisk launches Ozempic in India at ~$24/week, intensifying GLP-1 competition. 🏷️ Hashtags #Pharma #Biotech #FDA #DrugApprovals #MAndA #RareDisease #ObesityDrugs #Oncology #Autoimmune #GeneTherapy #EUPharma #GlobalHealth Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Stoc … ohorts - FDA engagement on U.S. site activation for Part 2 - EMA clinical trial application filing for EU expansion Read the full analysis on TLX591's differentiated pharmacology and commercial positioning: https://lnkd.in/g5BFHpxW Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 22,034 followers View Profile Follow E
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
RIDC Redoxoma – Trained people and their destinations CEPID Redoxoma RIDC Redoxoma En glish P or t uguês Sobre Sobre Membros Google Scholar Egressos Atividades Notícias Seminários Reuniões 2025 - Reunião Anual do CEPID Redoxoma 2022 – Reunião Anual do CEPID Redoxoma 2020 – Reunião do CEPID Redoxoma com o Comitê Consultivo 2019 – Reunião Anual do CEPID Redoxoma 2017 – 2 a Reunião do CEPID Redoxoma com o Comitê Consultivo 2017 – Reunião Geral com os Avaliadores da FAPESP 2016 – Reunião Anual do CEPID Redoxoma Impacto Científico, Social e Econômico Relatório Anual Relatórios do Cons
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Rare Kidney Disease Drug Development Summit 2026 | Hanson Wade posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin … turns 📢 Discovery on Target 2026 is coming—today is the May 8 Super Early Bird deadline to get the lowest rate: https://lnkd.in/exfbvgz Here are five key developments shaping drug discovery right now 👇 🧠 Science & Clinical Updates 🧬 Arvinas Announces FDA Approval of VEPPANU A major milestone for targeted protein degradation: VEPPANU becomes the first FDA-approved PROTAC therapy for ESR1-mutated ER+/HER2- advanced breast cancer. https://lnkd.in/efph4r59 🧪 Pinetree EGF
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Swiss Symposium in Pharmaceutical Medicine: Fighting Antimicrobial Resistance | ECPM / European Center of Pharmaceutical Medicine posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join … r portfolio company Gesynta Pharma that today announced that its clinical trial application for the company's Phase 2 trial of vipoglanstat for the treatment of endometriosis has been approved by the UK authorities. https://lnkd.in/dTcKpVva Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis - HealthCap https://www.healthcap.eu 18 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in THE BIO (더바이오) 4,782 followers 9
%PDF-1.3 %��������� 3 0 obj > stream xśˎ�6��z �h�� `d;�0 d�t� � �?0_I"�Ӣ�r c/�4���,����g�N}VZ�b�'��>}�>�Q˿��G����O��?�d�=�� �/,�z�Ũ�/�L�� �7�66�5+�� i�Z��~��t�c�%uH����-�Hf���w��(r\�S�X��}����q�{�����$ �� z�۵��N�xcG��} c1�Cں|�@�v�4�:��[�-��s��� _��b����>aX]�l�юw*�����oڋ�n�L C" �i[��Ή yCw�o�m� ��A����SO��$6�wh�����$c����m���Q��9ף}�?aϣ �3�}_n�� �C{%���M:gj:Gp� G�e�(����9�r��dα�h?ԓZI�e� �DHۣ�|����D�ap:�3pe��� s�L�p�1R[�E䏂�y9r%9v ��� J ).z�l�"�x9ctOD�(�=}�>����6YlA;�SӋD��B쩩9�1�E���� ]s�� ��go�(S;}"�w�""�Wd�5ZJ����1�� �dSrl�s�K�i����(p���D���� � … ��f���KB��̆�J�p~��Q��������S�E��Q� �s� �J�[i�3q u��0�s��r_�f���6`��vqd�,��oS6}RFp�d�+���� �bs�� KbxQD�-*J \ZNԗ(R���r�-r�4-��J��i����܍Z���u��*�Id�^�څb��5$�2�$��`��P0�Ăs����3�)�l!T� S�Xt d6�U��E+ _i΄�Hr� 8��*�nO{i}��7�r�a���è6� u&�v��d�n�D�ƅɨZ�{7sp� ����� �!����4���^M|ńW���ۆD!���n����se��s��N��$m�q�ͥ��gɪ�j���0' -�� O �q�$��h@�N �����Bܚ��@�j��K�R��#Q��i��=(�����u��/�?���r� ����$."� [��0j�D~���Gf� ��R�f�� ���l{���Sé��Q� �����ӥ�9��=s%�lZ�f٩ r�n-u�J
Confira a programação oficial da delegação brasileira nos EUA - Associação Brasileira das Indústria de Insumos Farmacêuticos Skip to content Home Quem somos Associados Projeto ApexBrasil Dicionário de Substâncias Farmacêuticas Business Intelligence Comex Notícias Índice de Notícias Associado em Foco Artigos bioBR Carolina Sellani Flávia Albuquerque Helena Faccioli Marcos Valadares Imprensa Eventos Cursos Fale conosco × Home Quem somos Associados Projeto ApexBrasil Dicionário de Substâncias Farmacêuticas Business Intelligence Comex Notícias Índice de Notícias Associado em Foco Artigos bio
Vivatech Home About RCGI Institutional Mission and Vision Team Principal Investigators Organisation Chart RCGI in Numbers Labs Multipurpose Equipment Intellectual Property – Patents Startups Carbonic MOF Tech Treetronics RCGI-USP Carbon Registry RCGI-USP Carbon Registry Specialists Methodology Inventory Our Content Our Events News Projects Nature Based Solution – (NBS) Carbon Capture and Utilization – CCU BioEnergy, Carbon Capture & Storage – (BE)CCS Greenhouse Gases – (GHG) Advocacy Power Systems Innovation Hub – InnovaPower Decarbonisation Centre 2 Centre – … [email protected] [email protected] Founder Sponsor Sponsors HOME TEAM LABs SCHOLARSHIP OPPORTUNITIES RCGI SYSTEM © Copyright 2025. Research Centre for Gas Innovation THURSDAY, 7 NOVEMBER SHORT ORAL SESSION F - 11h30 NBS26 (TV1) Soon BECCUS27 (TV2) Soon GHG28 (TV3) Soon ELECT29 (TV4) Soon DECARB30 (TV5) Soon THURSDAY, 9 NOVEMBER SHORT ORAL SESSION F - 14h00 0911 - EMS21 (TV1) EMS Alberto Fossa – Maurício Salles Andre Luis Ferreira Marques Solar energy and GHG: a Dat … bal value chains – ETE119 Melodie Kern Sarubo Dorth Sinegalia Methodology Proposal for Control Point Surveys: Considerations in the Context of Remote Forest Monitoring with Emphasis on Carbon Stock – ETE120 Mateus Castagnet Carbon Footprint Reduction through the Replacement of LPG with Biodigesters: A Case Study – ETE121 Leonardo de Freitas Economic viability of hydrogen – ETE122 Lauron Arend Business Models for the Brazilian Natural Gas Market in Time … n César Rodrigues de Araújo Synthesis and characterisation of nanomaterials for application in nanofiltration membranes and recovery of lithium from produced water – ETE190 Francisco Hélio Alencar Oliveira GHG reduction through Topology Optimization and Additive Manufacturing
Life Science Nation - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Mirscience Therapeutics will be attending BIO International Convention 2023, the biggest global event for the biotechnology industry. The event will host biotechnology and pharma leaders for one week… | Mirscience Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your
Pipeline – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Pipeline Our research is focused on diseases associated with longevity that affect the lives of millions of people, are lacking a specific treatment, and also are responsible for a decrease in the life quality of adults and the elderly. Our research is focused on diseases associated with longevity that affect the lives of millions of people, are lacking a specific treatment, and also are responsible for a decrease in the life
Mirscience Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Mirscience Therapeutics MirScience Therapeutics develops personalized RNA therapies targeting undruggable disease targets, focusing on diseases associated with longevity such as muscle atrophy, metabolic diseases like NASH, and cancer. Using their MIR-Discovery platform, they discover and develop microRNA molecules to create customized treatments, aiming to improve patients' quality of life and support healthy aging. Industries biotechnology Nr. of
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Angel Invest Boston | Libsyn Directory view_module Topics search search close Search Angel Invest Boston In the Decade of Biotech when there will be myriad opportunities to invest in angel-scale biotech startups. After decades of angel investing, I am focusing on the life science side of my portfolio and invite other angels to do the same. Here's why: https://www.labcoatventures.com/why-we-are-focused-on-early-stage-biotech/ I’m Sal Daher, host of the Angel Invest Boston Podcast. After immigrating to Boston as a child and attending Belmont High School, I studied engineering at MIT and Stanford … y /episode/index/show/angelinvestboston/id/29146113 info_outline Paul Hartung - Fund a Biotech Startup in Hard Times 12/13/2023 Paul Hartung - Fund a Biotech Startup in Hard Times Aging Fit Substack: Life science board member and advisor Paul Hartung is back with wise tips on how to fund your biotech startup in these had times. Listen or read below. Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson. Hi … artung Closed a Financing in the Midst of the Last Recession Seek Out the Right Grant Funding, Watch Expenses Pitch Contests Don’t Provide Much Money but Can Spotlight Your Startup Peer-Reviewed Publications Can Raise Visibility of Life Science Startups Look Outside Your Area, Consider Syndication Across Angel Groups Watch Out for Funds That Can’t Make Good on Term Sheets – It Happens More than You Think Be Upfront About Your Future Funding Plans “The nature of the investors … If they have a rash or a mole they're worried about, or a case like that, they submit a case, we review that case within 24 hours with our board-certified dermatologist, we call in prescriptions..." A Typical Consultation at Piction Health "... How did you discover this? How is it that it dawned on you that this is the direction to go in?..." "... Dermatologists loving working with us is one of our really important metrics that we want to make it really easy for them..." "..
#brazilianstartupday #bioconvention #innovation | Felipe V. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy P
Angel Invest Boston Toggle navigation About Episodes All Episodes Archives 2023 December November October September August July June May April March February January 2022 December November October September August July June May April March February January 2021 December November October September August July June May April March February January 2020 December November October September August July June May April March February January 2019 December November October September August July June May April March February January 2018 December November October September August July June May April Ma
Stream Milena Peregrino, PhD - Reversing Muscle Loss by Angel Invest Boston Podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Milena Peregrino, PhD - Reversing Muscle Loss by Angel Invest Boston Podcast published on 2023-10-18T05:40:25Z Angel Scale Biotech:   Brazilian startup MirScience Therapeutics is working on reversing muscle loss. I had an illuminating chat with co-founder Milena Peregrino, PhD about the technology and the company’s progress.    Sponsored by
"Reversing Muscle Loss" with Milena Peregrino, PhD — Angel Invest Boston | Mirscience Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
#genetherapy #rna #pharma | Carl Schoellhammer | 12 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy … the scientist discovering the biology of microRNA just received the 2024 Nobel Prize in Physiology or Medicine a few weeks ago! MicroRNA therapeutics companies include https://www.linkedin.com/company/cardior-pharmaceuticals , acquired by #NovoNordisk with its Phase 2 asset in #Heartfailure, #Resalis (just secured a deal with #Sanofi) with a Phase 1 asset, #ARTHEx, #Regulus, #Transcode Therapeutics, #MirScience, to name a few. Like Reply 1 Reaction Ravi Iyer 1y Report t
Skip to main content Issuu Search Read Features Flipbooks Transform any piece of content into a page-turning experience. Fullscreen Sharing Deliver a distraction-free reading experience with a simple link. Embed Host your publication on your website or blog with just a few clicks. Articles Get discovered by sharing your best content as bite-sized articles. Statistics Make data-driven decisions to drive reader engagement, subscriptions, and campaigns. Teams Enable groups of users to work together to streamline your digital publishing. Social Posts Create on-brand social posts and Articles in mi
Similar companies to Rome Therapeutics | VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up You must have cookies enabled to login Refresh (When Cookies Enabled) Forgotte … conditions. http://www.cartesiantherapeutics.com View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgrade to a Paid P … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Create a Free Account to Follow Companies To continue, pleas
%PDF-1.4 %���� 2378 0 obj > endobj xref 2378 45 0000000016 00000 n 0000004035 00000 n 0000004198 00000 n 0000006270 00000 n 0000006385 00000 n 0000007031 00000 n 0000007809 00000 n 0000007861 00000 n 0000007912 00000 n 0000007963 00000 n 0000008014 00000 n 0000008127 00000 n 0000008401 00000 n 0000009368 00000 n 0000009763 00000 n 0000010133 00000 n 0000010498 00000 n 0000010966 00000 n 0000011535 00000 n 0000011903 00000 n 0000011988 00000 n 0000016816 00000 n 0000023817 00000 n 0000109973 00000 n 0000129839 00000 n 0000130317 00000 n 0000152672 00000 n 0000290012 00000 n 0000419896 00000 n 0 … �G��X࣒X*M�}Tw海il�w�k��s�nt@���/����� �� endstream endobj 2419 0 obj >stream application/postscript particle style cyber network visualization wallpaper with text space Akash abstract particle tech technology digital data science web futuristic network system internet research innovation ai artificial intelligence cyber dynamic wallpaper visualization connectivity information background banner design concept net techno dot dotted blue particle style cyber network visualiza … 2023-05-24T15:15:46+05:30 Adobe Bridge 2022 (Windows) /metadata converted from application/postscript to application/vnd.adobe.illustrator Basic RGB 1 True False 49.180556 17.652778 Inches Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 0 0 0 Adobe PDF library 15.00 endstream endobj 2420 0 obj > endobj 1 0 obj >/Font >/ProcSet[/PDF/Text]/XObject >>>/Rotate 0/StructParents 1/TrimBox[0.0 0.0 496.063 612.283]/Type/Page/PieceInfo … ���pi��&���~�P\ -��D a%�A]��\��T�h���.��]�xY�:�� ��L���H�,��f w��{IrFp���s��)�����D��ɉy�&��m�L�ե�O�/�׳D� �����)����2� x�-dw�*~�3�e�` �og����}�c�gH������z�Q^?�ˣ"��.9�yt��:Mn'�I���e,KZ��G$G�� ���9�"��6� �b �顳����ķ����j�Vdi! ���L�� ����M�����Vq�f���EKi�i�4�g��� 3�M/h���M]�A!��� �}�=��ӟ\g=�C��]Xuk4��kh=,Yî�'#�{c|�~Hnk�V��!�Y �������Ж�̬�U�7s PN��ZU����>π�NeY go& k�Ѥ �!��8�t�f(��^�I��ᵞWޝ�qh%�k �܈� �ڂړRPV���i�����!���ȣD�Hɹli[��\�� … Э������Q {{\��� v|�����_����?��������g�Y endstream endobj 207 0 obj >stream application/postscript particle style cyber network visualization wallpaper with text space Akash abstract particle tech technology digital data science web futuristic network system internet research innovation ai artificial intelligence cyber dynamic wallpaper visua
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.7 %���� 2377 0 obj > endobj xref 2377 137 0000000016 00000 n 0000006092 00000 n 0000006227 00000 n 0000008074 00000 n 0000008609 00000 n 0000009033 00000 n 0000009540 00000 n 0000009579 00000 n 0000009694 00000 n 0000010173 00000 n 0000010761 00000 n 0000010874 00000 n 0000010999 00000 n 0000011256 00000 n 0000011777 00000 n 0000012028 00000 n 0000013050 00000 n 0000013350 00000 n 0000013719 00000 n 0000013990 00000 n 0000014250 00000 n 0000014877 00000 n 0000016133 00000 n 0000017019 00000 n 0000018236 00000 n 0000019520 00000 n 0000020082 00000 n 0000020347 00000 n 0000020962 00000 n … �&-�Zh(��O��W$��7�p���yӤ{���G/��v�+�� �� endstream endobj 2417 0 obj >stream application/pdf LSN Logo 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 Adobe Illustrator 26.3 (Windows) uuid:4f5ba327-632d-4d3e-9750-3dbb5ac53375 xmp.did:08a59ab9-3855-0341-99ff-96f16744b3b7 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b8b627b9-63dc-f348-9625-1ed948e71f30 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 d … Adobe PDF library 16.07 endstream endobj 2418 0 obj > endobj 2419 0 obj >stream application/postscript POLSINELLI-TAGLINE (Kelly Ludwig) 2023-12-11T09:48:12-06:00 2023-12-11T09:48:12-06:00 2023-12-11T09:48:12-06:00 Adobe Illustrator 28.0 (Macintosh) xmp.iid:b17b322d-6435-4a3e-a4ae-5611e5ee8738 xmp.did:04150ed5-a00d-4602-a0dc-3bf2c2dce1dc uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:8977f143-08ef-46b7-9cc6-fd85c3913a9e xmp.did:273aad7b-7c2c-4234-9706-4fb26a471748 uuid … 1 2023-12-08T08:59:07-06:00 Adobe Illustrator 28.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:273aad7b-7c2c-4234-9706-4fb26a471748 2023-12-10T16:10:51-06:00 Adobe Illustrator 28.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator s … K)�HHODq�C�2�c8�(N0ڀO*�VN�(CIƏ�IC���'��Ns�ի^)+���@F: }F�x�i�p���|�a�M=���rFp)ok� Y�� T�y��6����bh w�U ��P� g����_Lxle�M�v�#�e0�4����m\/���Q�V�0����Ep@ ��@�w���[}�c�WM�x�\Y9�\�xt*���U�鞄k�]Dݝ0ļ�o�3�����ǘ�W�����m�K��4���]Ձ�!H�7~A�� ���1X �X%H�=l��(f�SN 5��B�(e� ,���է,�+: �`�F,G� �Q�K��?2� � ��� :�e�B��=��=�)�����D6= �E��^r
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Biotechnology in Brazil: market trends and challenges in 2024 - Green Rock PT EN ES Home About us Portfolio People Content Investor area Contact LGPD PT EN ES Insights Biotechnology in Brazil: market trends and challenges in 2024 Other diseases are in the spotlight, the difference between techbio and biotech, difficulties in raising funds and what should change in the biotechnology market in the coming year Letícia Maia 15 min The arrival of 2024 may indicate a delicate period for those working in biotechnology. It is a fact that, the Brazilian market of Biotechs never achieved the ideal scena … ss that molecular problem, the methodology and mentality of a rare disease also apply to cancer.” All of this means that, by finding solutions for one type of disease, it is possible to find ways to solve others as well. In science, knowledge is integrated with each other, which is why investing in research for other diseases is also important. In addition, the current and future scenario of neurodegenerative and metabolic diseases also calls for urgent measures. According to … difficult for new entrepreneurs understand the elements that lead an investment fund to approve an initiative or not. Starting in the academic universe, it is common that the orientation for entering the business world is not as complete as it should be. This would be a side effect of the lack of integration between universities and Brazilian industry. To better understand the issue, it is worth recalling some of what happened in Brazil during the health crisis, what it was l
Sir: مرزا رضا ھاشم حیات Speech on Reault | Mir Science Enrichment Higher Secondary school
SWFL Marketplace/Buy Sell Trade Anything | Unbeatable Offer: Acquire 6 - 4 packs of 8.4oz cans of Original or Sour Patch case (mix and match 4 packs allowed) at an exclusive price of $10, while...
Biomedical Innovation in Brazil: an update | Research Communities by Springer Nature Skip to main content Share your thoughts about the Research Communities in our survey . News and Opinion Biomedical Innovation in Brazil: an update Four years ago, we wrote about biomedical innovation in Brazil[1]. The Covid-19 pandemic brought many changes. In the midst of several ongoing developments, the text below offers a glimpse of our fast-moving landscape. Published in Bioengineering & Biotechnology Sep 28, 2022 Denise Golgher and Rob Rodrigues 2 contributors Like Liked by Denise Golgher and 5 othe … w in figure 1) launched Skyhub, its accelerator/incubator and a venture capital fund, Kortex, in partnership with Fleury. DASA, Fleury, Rede D’Or have their corporate funds, so do the national pharmaceutical companies. What kind of innovation is being developed by these healthtechs? Most technologies aim at management solutions, electronic health records, access, telemedicine and market place [14, 15]. It all looks like the innovation ecosystem is serving healthcare systems f … innovation ecosystem. Vesper Ventures launched a biotechnology-focused venture fund and already has a portfolio of companies [16] . The Albert Einstein hospital in São Paulo is a protagonist of biomedical innovation. Its new endeavor, the program to innovate in biotechnologies, will hopefully follow the success of its incubator/accelerator Eretz Bio. The new program aims at stimulating the creation of new businesses in drug discovery and novel treatments, it is close to the … in with his research team from the A.C.Camargo Cancer Center (Figure 2). With a grant of more than R$ 20 million, CRIO was formed via the FAPESP Centers for Research in Engineering (CPE) program in partnership with the pharmaceutical company GSK. He is extremely happy with the new home, the funding and the future to come. Who wouldn’t be? Figure 2) Researcher Kenneth Gollob and team at the Albert Einstein Hospital’s new teaching building. [1] https://bioengineeringcommunity.n
Life Science Nation - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Green Rock: The Early Stage Founder's Guide Superscout Programs App Investors More Browse Opportunities VC Programs Index VC Fellowship Programs VC Scout Programs Become a Scout Apply Superscout App Browse By City Browse By University Browse By Accelerator In-Depth Venture Partner Deal memo Resources Scouts Home Learning Center Glossary Frequently Asked Questions Investors Investors Home Add Your Program Dealflow Hub Knowledge Hub Contact Us Articles VC Scout Programs: All You Need to Know From Scout to VC Partner: How Scouting Became the Fastest Track Into Venture Why Scout Programs Ar … w to Navigate Them Become a Scout Browse Opportunities VC Programs Index VC Fellowship Programs VC Scout Programs Become a Scout Apply Superscout App Browse By City Browse By University Browse By Accelerator In-Depth Venture Partner Deal memo Resources Scouts Home Learning Center Glossary Frequently Asked Questions Investors Investors Home Add Your Program Dealflow Hub Knowledge Hub Contact Us Articles VC Scout Programs: All You Need to Know From Scout to VC Partner: How … mily office for the Salomao and Zoppi families, the firm transitioned to a full fund manager, accepting third-party capital to expand its investment capabilities. Since its inception, Green Rock has deployed R$200 million (approximately $40 million USD) into various health-related enterprises, focusing on early-stage investments, particularly in Seed and Series A rounds. The firm screens over 1,000 healthcare companies annually, identifying high-potential startups that positi … Rock has also been recognized for its transition from a family office to a full fund manager, reflecting its growth ambitions and commitment to enhancing healthcare in Latin America. Frequently Asked Questions What are Green Rock's investment criteria? Green Rock focuses on early-stage investments in the healthcare sector, specifically in Seed and Series A rounds. They seek companies that enhance health experiences and address critical issues such as disease prevention, hea … on Browse By University Browse By Accelerator Learning Center VC Podcasts Scout Application Superscout Store Superscout App Learning Resources Scout Community VC Scout FAQ Deal Memo Tool Glossary Invest With Us Partner Resources Add Your Program AI Funding Hub Knowledge Center Case Studies Contact Us In-Depth Guides Head of Investor Relations Ven
"Reversing Muscle Loss" with Milena Peregrino, PhD — Angel Invest Boston Current Episode Home Actions Blurb Home Episodes Sal's startup sweetspot Invest Home Episodes ABOUT ABOUT BLOG Subscribe iTunes Google Play SUBSTACK Current Episode Home Actions Blurb Home Episodes Sal's startup sweetspot Invest Home Episodes ABOUT ABOUT BLOG Subscribe iTunes Google Play SUBSTACK October 17, 2023 Katharine Woodman-Maynard "Reversing Muscle Loss" with Milena Peregrino, PhD October 17, 2023 Katharine Woodman-Maynard Brazilian startup MirScience Therapeutics is working on reversing muscle los … f the efficacy data because it can increase the muscle mass until 20% after one application, which is a dream. Sal Daher: Cachexic patients who are suffering muscle loss from certain types of diseases like cancer. Milena Peregrino: Exactly. Everything that I have from data is everything pre-clinical. So everything was done with mice or rats. We also can increase the strength. This is the first thing that set us apart from our competitors, that we can increase the mass and the
Site Title Site Title Coming Soon Build a website. Sell your stuff. Write a blog. And so much more. Log in Start your website
MirScience – MirScience Therapeutics Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Developing therapies, delivering quality of life. Personalized RNA therapies that act undruggable targets, creating a new era of precision medicine. Learn More About Us Mirscience Therapeutics develops therapies for diseases associated with longevity. Using the Mir-Discovery platform , we have developed microRNA molecules that act on challenging targets, expanding treatments options for unmet medical needs that
Over two days, the Mirscience team—represented by William Silva, Milena Pelegrino, PhD and Lucas Ariel, PhD Ariel—participated in the largest Deep Tech event in Latin America: The Deep Tech Summit by… | Mirscience Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your
Mirscience Therapeutics - Investida por Green Rock PT EN ES Home About us Portfolio People Content Investor area Contact LGPD PT EN ES Mirscience Therapeutics Exit M&A Prospecting and developing microRNA/siRNA molecules for the treatment of diseases such as cachexia associated with cancer and sarcopenia in aging. Lucas Ariel William Silva MORE ABOUT THE COMPANY 01 Mirscience Therapeutics is a biotechnology startup that develops RNA molecules for the treatment of muscle and metabolic diseases. Through Mir-Plataform, the company prospects and develops microRNA/siRNA molecules for the treatme
William Silva – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline William Silva Phd, CSO, CO-Founder William Silva is a scientist and molecular biologist with 10 years of experience working in the field of microRNAs and exploring its ability to orchestrate the gene activity and therapeutic potential. Prior to founding Mirscience tx, was a post-doctoral fellow at the Institute of Biomedical Sciences from University of Sao Paulo where he also completed his PhD with an exchange program at
Mirscience Therapeutics - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Mem
Our Team – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Meet Our Team Lucas Rocha Phd, CEO, CO-Founder View bio William Silva Phd, CSO, CO-Founder View bio Milena Peregrino Phd, Drug Delivery Director View bio Ricardo Dilazzaro Msc, Board Member View bio Thomas Gerlach Phd, Senior Advisor View bio Edmar Ferreira Board Member View bio Vinicius Maracaja Phd, CTO View bio Not Sure What You Need? Simply give us a call and book an appointment for yourself. We are here to help. Walk into
Lucas Rocha – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Lucas Rocha Phd, CEO, CO-Founder Lucas Rocha is a scientist and entrepreneur enthusiastic about RNAs world, hard science innovation and drug discovery . He holds a degree in nursing from the State University of Piauí, a PhD in Pharmacology from the University of São Paulo, having worked in the area of microRNAs, liver diseases and bioinformatics. He participated in 2 pre-acceleration programs in Brazil and in 2019, he co-fo
Our Technology – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Our Technology Science behind microRNA What are microRNA ? microRNAs are a special class of small endogenous RNAs found out in the most diverse organisms with the role of ‘turn on’ or ‘turn off’ protein expression by inhibition of messenger RNA. How do microRNA act ? microRNAs act by silencing the mRNA (messenger RNA) that prevents protein expression, revealing a new understanding of the body’s functioning and emer
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Biotech Venture Capital Activity in Brazil Home About Meet the Team Hidden Layers Podcasts Nucleate Search Join Ecosystem Reports Hidden Layers Articles Biotech Venture Capital Activity in Brazil Brazilian VC funding in biotech is on the rise, with approximately 50 firms investing in a diverse range of biotech sectors. Lauren Stanwicks and Romina Soledad Horianski May 28, 2024 — 9 minutes read Highlights: Brazilian VC funding in biotech is on the rise, with approximately 50 firms investing in a diverse range of biotech sectors. Top players like GRIDS Capital, Vesper Ventures, and LifelyV … os, and LifelyVC. Top Funds Top three Brazilian VC funds GRIDS Capital , with a fund size of $161.1 million, was founded in 2016 and is headquartered in Sao Paulo. It operates as a deep tech venture capital firm, with investments spanning various sectors including AI, Robotics, Life Sciences, Tech Infrastructure, Energy, and Advanced Materials. While ranking first in biotech investments, this sector constitutes approximately 10% of their overall investment portfolio. Notable … unded in 2018 and based in Florianopolis, operates as a biotech-focused venture fund and venture builder. While ranking second in the number of biotech investments, all of its investments are focused on the biotech sector. Besides investments in companies such as Symbiomics, Cellertz Bio, and InEdita Bio, Vesper Ventures has recently invested in agriculture biotechs Hapiseeds and Reddot Bio. Aptah Bio, one of their portfolio companies, is a Brazilian biotech specializing in R … g Funds Although not among the top five firms, Green Rock, a healthcare-focused fund established in 2017, has started investing in biotech companies like NAIAD Drug Development and miRscience Therapeutics. MiRscience Therapeutics, a Brazilian seed-stage biotech company, specializes in developing artificial microRNAs to target aging diseases like sarcopenia (muscle loss) using their patented MIR-discovery platform. These investments are not yet reflected in Crunchbase's datase … ite the growing numbers and excitement on AI in Biotech, most of the technology application is still in its preclinical stages, having yet to prove itself. Figure 6. Areas of focus of 61 companies invested in by Brazilian Venture Capital Firms Figure 7. Technological assets of 61 companies invested in by Brazilian Venture Capital Firms Take
%PDF-1.6 %���� 1 0 obj >>> endobj 2 0 obj >stream 2024-04-12T13:16:45-03:00 2024-04-12T13:16:54-03:00 2024-04-12T13:16:54-03:00 Adobe InDesign 19.3 (Macintosh) uuid:ea98fd73-2398-9d4f-9e3e-c553253fcd9d xmp.did:99beb06a-c0d3-402f-9f10-6a69e67f8620 xmp.id:cfbab168-fc9e-45fa-a47e-7ee8c25de9d2 proof:pdf xmp.iid:8f8da373-45c3-4e47-b4f3-e24708fd1ba6 xmp.did:48368c43-9749-45a1-bc74-618dc6410cc0 xmp.did:99beb06a-c0d3-402f-9f10-6a69e67f8620 default converted from application/x-indesign to application/pdf Adobe InDesign 19.3 (Macintosh) / 2024-04-12T13:16:45-03:00 application/pdf Adobe PDF Library 17.0 … endobj 96 0 obj > endobj 97 0 obj > endobj 98 0 obj > endobj 127 0 obj >stream application/postscript logo_sindusfarma_final_LR_V1_CMYK Len52 2022-10-25T16:21-03:00 2022-10-25T16:21-03:00 2022-10-25T16:20:59-03:00 Adobe Illustrator 27.0 (Macintosh) xmp.iid:7297ce31-ce6b-4a17-99af-c3fdfcd77776 xmp.did:7297ce31-ce6b-4a17-99af-c3fdfcd77776 uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:1848120e-5dc3-43d9-82b5-d8b2e2b108db xmp.did:1848120e-5dc3-43d9-82b5-d8b2e2b108db uuid … CMYK 74.972147 67.919427 67.049664 90.145719 endstream endobj 126 0 obj >stream application/postscript Print (Arte Negrito) 2024-04-08T20:01:29-03:00 2024-04-08T20:01:29-03:00 2024-04-08T20:01:29-03:00 Adobe Illustrator 28.3 (Macintosh) xmp.iid:b11e2b76-c64e-494e-bb32-99c65398e0ed xmp.did:b11e2b76-c64e-494e-bb32-99c65398e0ed uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:447c8b0b-9cda-bd48-bcc1-24171fd14f2f xmp.did:447c8b0b-9cda-bd48-bcc1-24171fd14f2f uuid:5D20892493 … f2f 2024-04-08T13:56:49-03:00 Adobe Illustrator 27.8 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:b11e2b76-c64e-494e-bb32-99c65398e0ed 2024-04-08T20:01:29-03:00 Adobe Illustrator 28.3 (Macintosh) / Print Adobe Illustrator False False 1 595.275574 841.889832 Points Cyan Magenta Yellow Black Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.00000 … .000000 LAB 69.803925 -45 -7 PANTONE 425 CVC SPOT 100.000000 LAB 40.392159 -2 2 application/postscript (Arte Negrito) (Adobe Illustrator Artwork) endstream endobj 72 0 obj > endobj 88 0 obj >stream H��Wێ�H}�W�cZ�;}�EH�̅aaH�/�z3xq��N`�_�U�v���y�v��ԩSe�$�� �w�F7S���o�G��:R t �4�,V =YyJH�"�,�����F {d �,� �7&S�9�:�=FI��8v=O��߅� !I�a_�� �
Resalis Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Resalis Therapeutics Resalis Therapeutics is dedicated to developing RNA-based therapies that address the root causes of complex metabolic disorders. With expertise in non-coding RNA and lipid metabolism, the company is advancing RES-010, a promising therapy currently in Phase 1 clinical trials, targeting obesity and fatty liver disease. The company aims to offer safe, effective, and disease-modifying treatments, expanding its pipeline to include therapies … didate RES-010. Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases Feb 22, 2023 - Initial funding to develop RNA-based therapies. View All News Show less Similar organizations Browse all ORGANIZATIONS Member Member Member Member Member Member JOIN OUR MAILING LIST Stay Connected with MTEC Keep up with active and upcoming solicitations, MTEC news and other valuable information. MTEC For federal agencies
2026 BIO International Convention | Exhibitor Floor Plan 2026 BIO International Convention Map Your Show DOWNLOAD Selected Exhibitor Search Results Available Booth Zoom In Zoom Out Max Fit Highlight Available Booths Display Booth Dimensions Orientation: Landscape Portrait Print Screenshot Include Booth Results: None Search Results Include Exhibitor Names on Floor Plan: Yes Print Hall(s): Current Hall All Halls Show Available Booths Your floor plan printout is processing. If you selected multiple halls it may take a minute for your print to finish. Loading... Creating Printout..... PRINT MY FLO
--> Navigating Biotechnology's 'Valley of Death' top of page Home About Solutions Insights Contact Policies Privacy Policy Compliance Policy Cookies Policy Terms and conditions Informed consent paulocfernandes LinkedIn All posts Navigating Biotechnology's 'Valley of Death' Paulo Cesar Fernandes Sep 9, 2024 4 min read By Paulo Fernandes & Lucas Ariel Fernandes The biotechnology industry currently faces significant challenges, especially for early-stage companies trying to navigate the complex “Valley of Death.” This term refers to the critical phase in which biotechnology sta
Our paper on microRNAs for osteosarcopenia | Mirscience Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Thomas Gerlach – MirScience Skip to content Home About Us Our Team Our Technology Pipeline Contact Us Contact Us Main Menu Home About Us Our Team Our Technology Pipeline Thomas Gerlach Phd, Senior Advisor Pharma professional with more than 30 years of experience in biopharmaceuticals and venture capital, who worked in big multinational companies like Knoll and Novartis in Germany and Switzerland, but also in successful startups like Actelion, (Switzerland and Brazil), early startup like Biozeus (Brazil) and in venture capital in life science. During his career, he worked in drug developm
Mirscience Therapeutics will be attending BIO International Convention 2026, taking place from June 15–18, 2026. We look forward to connecting with investors, pharmaceutical partners, biotech… | Mirscience Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices